Thus, the current standard therapies still rely on platinum-based drugs (cisplatin or oxaliplatin) that target DNA and induce the tumor suppressor gene p53, which, however is inactivated in more than 60% of gastric cancers [4,5,6]. This evidence concerns the gene TP53 and gastric cancer.